Log In
Print
BCIQ
Print
Print this Print this
 

rhNAGLU (SBC-103)

  Manage Alerts
Collapse Summary General Information
Company Alexion Pharmaceuticals Inc.
DescriptionRecombinant human N-acetylglucosaminidase alpha (NAGLU)
Molecular Target N-acetylglucosaminidase alpha (NAGLU)
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase I/II
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo B syndrome)
Regulatory Designation U.S. - Fast Track (Treat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo B syndrome));
U.S. - Orphan Drug (Treat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo B syndrome));
EU - Orphan Drug (Treat mucopolysaccharidosis IIIB (MPS IIIB, Sanfilippo B syndrome))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$8,788.4M

$4,473.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today